| 9.8328 0.353 (3.72%) | 05-14 15:24 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 11.72 | 1-year : | 13.68 |
| Resists | First : | 10.03 | Second : | 11.72 |
| Pivot price | 9.26 |
|||
| Supports | First : | 9.1 | Second : | 8.52 |
| MAs | MA(5) : | 9.6 |
MA(20) : | 9.33 |
| MA(100) : | 8.91 |
MA(250) : | 8.47 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 81.8 |
D(3) : | 73.9 |
| RSI | RSI(14): 63.6 |
|||
| 52-week | High : | 12.48 | Low : | 5.44 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ KURA ] has closed below upper band by 1.4%. Bollinger Bands are 13.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.55 - 9.59 | 9.59 - 9.63 |
| Low: | 8.65 - 8.7 | 8.7 - 8.74 |
| Close: | 9.4 - 9.48 | 9.48 - 9.55 |
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Thu, 14 May 2026
Kura Oncology (KURA) Receives a Buy from Barclays - The Globe and Mail
Wed, 13 May 2026
Transcript : Kura Oncology, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 03 - marketscreener.com
Wed, 13 May 2026
KURA: Ziftomenib and darlifarnib drive growth with strong uptake, broad trials, and promising new data - TradingView
Wed, 13 May 2026
Kura Oncology, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Tue, 12 May 2026
Q1 2026 Kura Oncology Inc Earnings Call Transcript - GuruFocus
Tue, 12 May 2026
Kura Oncology Inc earnings matched, revenue fell short of estimates - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 89 (M) |
| Shares Float | 65 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 96.5 (%) |
| Shares Short | 15,010 (K) |
| Shares Short P.Month | 14,380 (K) |
| EPS | -3.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.98 |
| Profit Margin | 0 % |
| Operating Margin | -497.7 % |
| Return on Assets (ttm) | -25.4 % |
| Return on Equity (ttm) | -94.9 % |
| Qtrly Rev. Growth | -67.9 % |
| Gross Profit (p.s.) | -2.07 |
| Sales Per Share | 0.76 |
| EBITDA (p.s.) | -3.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -64 (M) |
| Levered Free Cash Flow | -142 (M) |
| PE Ratio | -3.13 |
| PEG Ratio | 0 |
| Price to Book value | 5.01 |
| Price to Sales | 13.06 |
| Price to Cash Flow | -13.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|